Progressive multifocal leukoencephalopathy (PML) is a rare viral infection of the central nervous system (CNS) occurring in immunocompromised patients. Recovery of JC virus (JCV) specific T cell immune responses is the only available therapeutic option. JCV may use immune checkpoint inhibitory pathways to evade immune responses. The aim of this project is to determine whether T cell expression of immune checkpoint molecules is correlated to antiviral T cell responses, control of JCV replication and PML outcome. Immune checkpoint blockade by reversing T cell exhaustion may represent a therapeutic perspective for PML.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Immune checkpoint molecules
Timeframe: 1 month
Immune checkpoint molecules
Timeframe: 3 months
Immune checkpoint molecules
Timeframe: 6 months
JC viral load
Timeframe: 1 month
JC viral load
Timeframe: 3 months
JC viral load
Timeframe: 6 months
Detection of immune responses against a JCV peptide library
Timeframe: 1 month
Detection of immune responses against a JCV peptide library
Timeframe: 3 months
Detection of immune responses against a JCV peptide library
Timeframe: 6 months